Tsingke Biotech hosts the 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing, bringing together top biotech experts to discuss RNA-based therapeutics and innovation.
 |
| Over 100 scientists and biotech leaders attended the Tsingke Biotech 2025 roundtable to discuss breakthroughs in oligonucleotide drug development, with insights into RNA delivery and manufacturing. Image: TB |
Beijing, China — July 29, 2025:
Tsingke Biotech, a leader in synthetic biology and nucleic acid solutions, successfully hosted the 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing. The event brought together more than 100 scientists, biotech executives, and R&D leaders to discuss the latest advancements in RNA-based therapeutics, focusing on critical areas such as synthesis, delivery technologies, and the industrialization of oligonucleotide drug development.
The roundtable featured insightful keynote presentations and an engaging panel discussion, which delved into some of the most pressing challenges and opportunities in the field of RNA therapeutics. One of the key topics of discussion was the growing importance of delivery systems in the success of oligonucleotide therapeutics. Advances in structural innovation, such as the development of circular and condensed nucleic acid structures, were highlighted for their potential to improve the stability and distribution of therapeutic agents. These innovations are expected to play a crucial role in overcoming the complex biological barriers that hinder the delivery of RNA-based drugs to their targets.
Another key issue addressed was the challenge of targeting non-hepatic tissues and the central nervous system (CNS). Researchers discussed new delivery strategies that involve glycosylated carriers and ring-shaped condensation mechanisms. These approaches have shown promise in overcoming difficult physiological barriers, such as the blood-brain barrier, which is a significant hurdle for many CNS-targeting therapies.
The development of aptamer-based drugs also featured prominently at the roundtable. Researchers shared advances in screening techniques, including a combination of solid-liquid interface selection and fluorescence-based validation, to identify high-affinity aptamer candidates. These methods are becoming increasingly important for precision medicine, enabling the development of more targeted and effective treatments.
The panel discussion also addressed several key challenges facing the industry, such as China's gap in delivery platform technology and the race for securing core patents in the field. Experts also highlighted the importance of early-stage Chemistry, Manufacturing, and Controls (CMC) planning, stressing that a solid foundation in these areas is crucial for the successful translation of novel therapies from the lab to the clinic. Additionally, the discussion touched on the need to address cost barriers, clinical acceptance, and intellectual property (IP) risks within China’s rapidly developing biotech ecosystem.
As the host and initiator of this roundtable, Tsingke Biotech showcased its cutting-edge progress in high-purity oligonucleotide synthesis, chemical modification, and IND-enabling raw material support. The company emphasized its role in bridging the gap between research innovation and clinical application, with a focus on accelerating the translation of RNA therapeutics into real-world treatments.
A Tsingke Biotech spokesperson remarked, "The next decade will define the role of oligonucleotides in precision medicine. Tsingke will continue to serve as a connector between breakthrough innovation and its application, empowering therapeutic developers worldwide to turn their ideas into actionable treatments."
The roundtable was a significant step forward in advancing the development of RNA-based therapeutics and underscored China's growing importance in the global biotech landscape. The discussions and collaborations formed at the event are expected to pave the way for the next generation of oligonucleotide-based drugs, transforming precision medicine and addressing some of the most challenging diseases of our time.